LFCR

#3707
Lifecore Biomedical, Inc. - Common Stock
4.4 9 USD
-0.01%
Market Price
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
4.46
4.54
Rango anual
3.63
8.98
Cambio diario
-1.10%
Variación mensual
+2.75%
Variación en los últimos 6 meses
-38.41%
Cambio anual
-41.00%
Cierres anteriores
4.5 4
Open
4.4 6
Mínimo
4.4 6
Máximo
4.5 4
Volumen
66
Ver el calendario completo

Financials

Visión general Informes Estadísticas Documents

2026

Current report, Q3 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
LIFECORE BIOMEDICAL, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
LIFECORE BIOMEDICAL, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q1 FY2026
8-K

2025

Current report, Q4 FY2025
LIFECORE BIOMEDICAL, INC. current report, Q4 FY2025
8-K

LIFECORE BIOMEDICAL, INC. current report, Q2 FY2025

Full document

Business Context and Reporting Period

Company: Lifecore Biomedical, Inc. (LFCR)
Filing Type: Form 8-K (Current Report)
Report Date: April 3, 2025
Reporting Period: Fiscal quarter ended February 23, 2025
Context: The filing announces the issuance of a press release regarding consolidated financial results for the quarter ended February 23, 2025, and the availability of investor presentation materials on the company website.

Key Financial Metrics

The provided Form 8-K text serves as a notification of the release of financial results and does not contain specific numerical data. Consequently, the following metrics are not available in this document:

  • Revenue: Not provided in filing text.
  • Profit: Not provided in filing text.
  • Cash Flow: Not provided in filing text.
  • Margins: Not provided in filing text.
  • Debt and Liquidity: Not provided in filing text.

Material Changes

The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.

Guidance, Outlook, and Risks

Management Commentary and Outlook: The company made investor presentation materials available on its website (Exhibit 99.2), which may contain forward-looking statements, though the specific content of these materials is not detailed in the 8-K text.
Risks and Contingencies: No specific risks, contingencies, or unusual items are described in the body of this filing. The filing includes standard disclaimers that the furnished information is not deemed "filed" under Section 18 of the Exchange Act.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for specific revenue, earnings, and margin figures for the quarter ended February 23, 2025.
  • Examine Exhibit 99.2 (Investor Presentation) for management's outlook, guidance, and strategic updates.
  • Verify the company's stock trading symbol (LFCR) on the NASDAQ Global Select Market.
  • Confirm the fiscal quarter end date (February 23, 2025) aligns with the company's 52-53 week fiscal year structure.

Noticias